LUXEMBOURG—Manwin has decided to set new best practices regulations for all performers and third party producers hired to create content for its websites.
In its proposal, Manwin supports the system put in place by the APHSS, while also moving beyond the standard industry practice of 30-day interval testing.
The APHSS has set forward a best practices guideline and system that allows performers, producers, and agents to create a controlled work environment.
It includes consistent standards and guidelines for testing and treatment of adult performers, a secure database that ensures performer privacy and protects producer liability, protocol for performer support in the event of a positive HIV test result – including testing of 1st and 2nd generation partners—as well as health and safety resources provided for producers and performers.
Following months of research, and meetings with various doctors and medical experts from the most respected universities and health institutions in North America, Manwin has decided to implement additional rules for anyone involved in producing content for its sites.
The company will require FDA-approved tests from the clinics listed on the APHSS.org website, specifically the HIV-1 Aptima RNA Qualitive Assay. In addition, the company will require 15-day interval testing for performers.
As of July 1, 2012, adult entertainers performing in scenes commissioned for websites belonging to Manwin will have to provide health tests that are no older than 15 days. Manwin will pay for all additional tests needed under these new rules, in case a performer works for any of the company’s brands multiple times in a 30-day period.
Manwin expects producers, performers and agents to be in full compliance with these new regulations, and looks forward to working with the FSC in setting the highest possible standards for the industry.